Recce Pharmaceuticals Advances Testing of Skin Infection Gel

2 min read | October 09, 2024 06:06 PM AEDT | By Team Kalkine Media

Google News:

Recce Pharmaceuticals Advances Testing of Skin Infection Gel — Image source: Shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

Highlights

Recce Pharmaceuticals progresses its Phase II trial for a topical gel.

Early data shows the gel is safe and demonstrates positive antibacterial effects.

Recruitment for the trial is on track to finish by the end of the year.

Recce Pharmaceuticals Ltd (ASX:RCE) has made significant progress in its ongoing clinical trial for a promising treatment targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The company recently reached the halfway point in its Phase II study, which is investigating the effectiveness of RECCE 327 topical gel, also known as R327G, for treating various bacterial skin infections such as diabetic foot infections and other wound-related conditions. This milestone positions the company as a noteworthy ASX healthcare stock, advancing innovative treatments in the medical sector.

Trial Shows Positive Results So Far

Fifteen participants have been dosed so far in the study, which aims to evaluate the safety and efficacy of R327G. Early evidence from the trial has been encouraging, showing the gel is both safe and well-tolerated in human subjects. Furthermore, there are promising signs of antibacterial activity in patients, suggesting the gel could potentially be used in different formulations for broader applications.

Market Potential for Skin Infection Treatments

The need for effective treatments for ABSSSIs is substantial, especially considering the severity of these infections. As Recce Pharmaceuticals continues its clinical progress, the market for such treatments is projected to expand significantly over the coming years.

Clinical Milestones on Track

The ongoing Phase II trial, designed to enrol 30 participants, is an open-label pilot study. This trial will assess the bioavailability and absorption of R327G when applied directly to infected areas. Recce is optimistic about completing recruitment by the year’s end, positioning the company for further development steps.

Investors responded positively to this progress, reflecting confidence in Recce Pharmaceuticals' continued advancements in this area.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.